NP3-146

NP3-146 (NLRP3-IN-5) is an experimental drug which acts as an inhibitor of the NLRP3 inflammasome. It inhibits the release of interleukin-1β and interleukin-18 which is usually triggered by inflammatory stimuli, and so terminates the resulting signalling cascade. It is used for research into various conditions in which chronic inflammation plays a role.^[1]^[2]^[3]^[4]

References

↑ "Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition". Journal of Molecular Biology 433 (24). December 2021. doi:10.1016/j.jmb.2021.167309. PMID 34687713.
↑ "Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation". European Journal of Medicinal Chemistry 257. September 2023. doi:10.1016/j.ejmech.2023.115542. PMID 37290185.
↑ "Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction". Pharmacological Reviews 75 (3): 487–520. May 2023. doi:10.1124/pharmrev.122.000629. PMID 36669831.
↑ "Design, synthesis and biological evaluation of sulfonylurea derivatives as NLRP3 inflammasome inhibitors". Bioorganic & Medicinal Chemistry Letters 114. December 2024. doi:10.1016/j.bmcl.2024.129987. PMID 39395633.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/NP3-146. Read more

[1] "Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition". Journal of Molecular Biology 433 (24). December 2021. doi:10.1016/j.jmb.2021.167309. PMID 34687713.

[2] "Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation". European Journal of Medicinal Chemistry 257. September 2023. doi:10.1016/j.ejmech.2023.115542. PMID 37290185.

[3] "Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction". Pharmacological Reviews 75 (3): 487–520. May 2023. doi:10.1124/pharmrev.122.000629. PMID 36669831.

[4] "Design, synthesis and biological evaluation of sulfonylurea derivatives as NLRP3 inflammasome inhibitors". Bioorganic & Medicinal Chemistry Letters 114. December 2024. doi:10.1016/j.bmcl.2024.129987. PMID 39395633.

[1]

[2]

[3]

[4]

NP3-146

Topic: Chemistry

See also

References